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The mechanism of lipopolysaccharide (LPS) transport
in Gram-negative bacteria from the inner membrane to
the outer membrane is largely unknown. Here, we inves-
tigated the possibility that LPS transport proceeds via a
soluble intermediate associated with a periplasmic
chaperone analogous to the Lol-dependent transport
mechanism of lipoproteins. Whereas newly synthesized
lipoproteins could be released from spheroplasts of
Escherichia coli upon addition of a periplasmic extract
containing LolA, de novo synthesized LPS was not re-
leased. We demonstrate that LPS synthesized de novo in
spheroplasts co-fractionated with the outer membranes
and that this co-fractionation was dependent on the
presence in the spheroplasts of a functional MsbA pro-
tein, the protein responsible for the flip-flop of LPS
across the inner membrane. The outer membrane local-
ization of the LPS was confirmed by its modification by
the outer membrane enzyme CrcA (PagP). We conclude
that a substantial amount of LPSwas translocated to the
outer membrane in spheroplasts, suggesting that trans-
port proceeds via contact sites between the two mem-
branes. In contrast to LPS, de novo synthesized phos-
pholipids were not transported to the outer membrane
in spheroplasts. Apparently, LPS and phospholipids
have different requirements for their transport to the
outer membrane.
The cell envelope of Gram-negative bacteria consists of an
inner (IM)1 and an outer membrane (OM) separated by the
peptidoglycan-containing periplasm. The lipidic components of
the OM, phospholipids, lipopolysaccharide (LPS), and lipopro-
teins, are all synthesized in the IM. Because of their hydropho-
bic lipid moiety, transport directly through the aqueous
periplasm is thermodynamically unfavorable. Therefore, the
transport process is expected to require a special machinery,
including, for example, a soluble periplasmic chaperone that
shields the lipid moiety. Alternatively, transport might proceed
directly from IM to OM via a macromolecular complex bridging
the periplasm. The existence of contacts between IM and OM
has been reported previously (1).
LPS can be divided in a hydrophobic lipid A part and a
hydrophilic part, consisting of the oligosaccharide core and an
O-antigen. In Escherichia coli K-12, lipid A consists of a gluco-
samine dimer substituted with, in general, six acyl chains. The
core of the LPS consists of 3-deoxy-D-manno-octulosonic acid
(Kdo) residues, which are attached to lipid A, and other sugars
(2). The biosynthesis is well described (2), and, recently, con-
siderable progress has been made in understanding the mech-
anism of its transport from the site of synthesis to its destina-
tion. The translocation of the lipid A core moiety of LPS across
the IM requires the MsbA protein (3–5). When a temperature-
sensitive (ts) msbA mutant was shifted to the restrictive tem-
perature, LPS was found to accumulate in the IM (4). MsbA is
a transporter of the ATP-binding cassette protein family, and
the presence of (Kdo)2-lipid A, a precursor of LPS, increased the
ATPase activity of MsbA reconstituted in liposomes (6). The
crystal structure of MsbA has been solved (7). Additionally, it
was recently shown that an OM protein designated Imp is
required for the correct localization of LPS at the cell surface of
Neisseria meningitidis. This protein is likely involved in a very
late step in LPS transport, presumably the flip-flop from the
inner to the outer leaflet of the OM (8). However, the transport
of LPS through the aqueous periplasm remains enigmatic.
Potentially, LPS could be transported across the periplasm
in a way analogous to lipoprotein transport. The transport of
lipoproteins, such as Braun’s lipoprotein, also known as Lpp, to
the OM is reasonably well understood nowadays. Lipoproteins
are N-terminally lipidated (9, 10) after translocation across the
IM via the Sec machinery and then recruited by the IM-located
LolCDE complex, which, like MsbA, belongs to the ATP-bind-
ing cassette transporter superfamily (11). This complex utilizes
ATP to enable the periplasmic chaperone LolA to form a com-
plex with the lipoprotein (11, 12). After transport across the
periplasm, lipoproteins are transferred from the LolA-lipopro-
tein complex to the receptor LolB in the OM (13).
In this study, we have investigated whether LPS can be
released from spheroplasts by periplasmic components. How-
ever, we found that LPS is transported to the OM in sphero-
plasts, suggesting that transport proceeds via contact sites
between the membranes.
EXPERIMENTAL PROCEDURES
Strains and Media—E. coli strains used in this study are listed in
Table I. Cells were grown in LB medium (14), synthetic minimal me-
dium (SV) (15) supplemented with 0.2% glucose, and 10 g/ml thiamine
or on LB agar plates. Ampicillin was supplied, where necessary, at a
final concentration of 100 g/ml. Experiments with genetically modified
organisms were performed under license number GGO 99-139/2.
Plasmid Constructions—The plasmids used in this study are listed in
Table I. To clone the crcA gene, a DNA fragment containing this gene
was amplified from genomic DNA obtained from E. coli K-12 strain
MC4100 by PCR performed in a volume of 50 l with 1.75 units of
Expand High Fidelity enzyme mix (Roche Applied Science), 0.2 mM
dNTPs, 1.5% dimethyl sulfoxide and 25 pmol of primers (Isogen) with
the sequences AACATATGAACGTGAGTAAATATGTCG (NdeI restric-
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tion site is underlined) and AAGGATCCTCAAAACTGAAAGCGCATC
(BamHI site is underlined). After initial denaturation for 3 min at
94 °C, 30 cycles of 1 min at 94 °C, 1 min at 55 °C, and 90 s at 72 °C were
performed, followed by 10 min at 72 °C. The PCR product was cloned
into pCRII-TOPO according to manufacturer’s protocol (Invitrogen).
From the resulting plasmid, pCRII-TOPO-crcA, an NdeI-BamHI frag-
ment was cloned into pET11a, and from the resulting construct the
sequence of crcA was confirmed. An XbaI-HindIII fragment from
pET11a-crcA, including the ribosome-binding site of pET11a, was
cloned into pMMB67EH, yielding pMMB67EH-crcA.
Preparation of Spheroplasts—Cultures, pregrown overnight at 37 °C
in either SV or LB medium for subsequent protein or LPS labeling,
respectively, were diluted 10-fold in the same medium and grown to an
optical density at 660 nm (A660) between 0.4 and 0.7. Cells from a 10-ml
culture were converted to spheroplasts as described (16). Briefly, the
cells were pelleted and washed in 2 ml of 10 mM Tris-HCl (pH 7.5), 0.75
M sucrose and resuspended in 500 l of the same buffer. Subsequently,
25 l of lysozyme (2 mg/ml) and 1050 l of 1.5 mM EDTA were added,
and the mixture was incubated on ice for 10 to 20 min. After this
procedure, more than 99% of the cells were converted to spheroplasts as
evaluated under a light microscope.
Isolation of Periplasmic Fractions—MC4100 cells from five 1-liter
cultures grown in LB at 37 °C to an A660 of 0.6 were pelleted and
converted to spheroplasts as described above in a total volume of 1.2
liters. After removal of the spheroplasts by centrifugation in an
SLA1500 rotor (Beckman Coulter) at 10,000 rpm for 10 min at 4 °C and
of residual membranes by ultracentrifugation in a 60 Ti rotor (Beckman
Coulter) at 38,000 rpm for 30 min at 4 °C, the supernatant was concen-
trated to15 ml in an Amicon 8400 concentrator using a 10-kDa cut-off
polyethersulfone filter and nitrogen gas. The periplasmic fraction was
finally dialyzed against 20 mM Tris-HCl (pH 8.0) at 4 °C. Aliquots were
immediately frozen in liquid nitrogen, stored at 80 °C and used only
once.
Quantitative Western Blotting—A dilution series of purified LolA
with known protein concentration was loaded as a standard next to a
dilution series of periplasmic extracts on an SDS-polyacrylamide gel,
and the proteins were blotted onto a nitrocellulose membrane (17).
After immunodetection with antiserum directed against LolA, peroxi-
dase-conjugated secondary antibody, H2O2, and 4-chloro-1-naphthol
(18), the concentration of LolA in the periplasmic extracts was esti-
mated by comparing the intensity of the bands with the standard.
Spheroplast Release Assay—One-tenth of a spheroplast suspension
was added to 375 l of SV supplemented with 0.25 M sucrose. A con-
centrated periplasmic fraction (usually 50 l), purified LolA (4 g), or
Tris-HCl (pH 8.0) was added to the mixture. To label de novo synthe-
sized proteins, the spheroplasts were incubated with 5 Ci [35S] cys-
teine/methionine (Promix label) for 3 min at 30 °C followed by a chase
for 4 min with 2 l of 0.1 M unlabeled cysteine/methionine. LPS and
phospholipids were labeled by incubating the spheroplasts for 4 min at
37 °C with 2 Ci of [1-14C]sodium acetate, followed by a chase with 10
l of 0.48 M unlabeled sodium acetate for 4 min. Alternatively, LPS was
labeled by incubation of the spheroplasts with 2 Ci N-acetyl-D-[1-
14C]glucosamine for 25 min. All radioactive compounds were purchased
from Amersham Biosciences. After labeling, spheroplasts were chilled
on ice for at least 1 min and centrifuged at 16,400  g in an Eppendorf
centrifuge to separate the spheroplasts from the medium. Spheroplasts
were resuspended in water, and hereafter, the proteins present in the
spheroplast and supernatant fractions were precipitated by adding 0.10
volume of 70% (w/w) trichloroacetic acid. Precipitated proteins were
resuspended in SDS buffer followed by immunoprecipitation as de-
scribed (19) with polyclonal rabbit antisera directed against Lpp or
OmpC and analysis of the precipitated proteins by SDS-PAGE (20) and
subsequent autoradiography.
Notably, spheroplasts lost the ability to release Lpp in the presence
of LolA and of OM proteins (OMPs) into the medium if they were
collected by centrifugation before the labeling procedure (data
not shown).
Purification of Radiolabeled LPS—E. coli O111::B4 cells were la-
beled overnight in 10 ml LB medium with 2 Ci of [1-14C]sodium
acetate. Cells were collected by centrifugation for 10 min at 5000 rpm in
an Eppendorf centrifuge, and LPS was extracted with the hot-phenol
method (21). The LPS concentration was determined by measuring the
Kdo content of the samples (22).
Isopycnic Sucrose Gradient Centrifugation—After labeling for 1 min
with 2 Ci of [1-14C]sodium acetate and a 30-min chase period with 15
l of 0.48 M unlabeled acetate, cells or spheroplasts were resuspended
in 1 ml of 10 mM Tris-HCl, 1 mM EDTA (pH 8.0). Alternatively, 10 ml of
mid-log cells were converted into spheroplasts as described and resus-
pended into LB containing 0.25 M sucrose (end volume of 22 ml).
Spheroplasts or intact cells were labeled for 25 min with 80 Ci of
[1-14C]sodium acetate. The cells or spheroplasts were broken by two
40-watt pulses of 10 s each using a microtip on a Sonifier B-12 (Branson
Sonic Power Co.) and cooling on ice between the pulses. The sonicated
samples were applied to the top of a discontinuous sucrose gradient
formed by layering sucrose solutions (buffered with 10 mM Tris-HCl, 1
mM EDTA (pH 7.5)) into a centrifuge tube as follows: 2 ml of 56%
sucrose; 4.75 ml of 42% sucrose and 4.25 ml of 25% sucrose (all w/w).
After 22.5-h centrifugation at 38,000 rpm in a Beckman SW41 rotor at
4 °C, 1-ml fractions were collected starting from the top (23). Lactate
dehydrogenase activity (24) was used as an IM marker. The porins,
visualized by Coomassie staining after SDS-PAGE (20), were used as a
marker for the OM.
LPS Analysis—LPS was routinely analyzed on SDS-polyacrylamide
gels containing 14% acrylamide and subsequently visualized by silver
staining (25) and/or autoradiography. LPS from sucrose fractions was
precipitated by adding 0.10 volume of 70% trichloroacetic acid. Pellets
were resuspended in 160 l of phosphate-buffered saline (pH 7.4), and
lipid A was subsequently isolated as described (26). The total amount of
radioactive lipid A in each fraction was determined by scintillation
counting in 5 ml of Lipoluma Plus (LUMAC) using a 1209 Rackbeta
LSC (LKB Wallac) and/or analyzed by TLC as described (26).
Analysis of CrcA/PagP-mediated LPS Modifications—Cells contain-
ing pMMB67EH-crcA or the empty vector pMMB67EH were pregrown
in LB medium at 37 °C, diluted 10-fold in 5 ml of LB containing 1 mM
isopropyl -D-thiogalactopyranoside to induce crcA expression, and
grown for 80 min when the A660 reached 0.5. Hereafter, the cells were
converted to spheroplasts. These spheroplasts or an equivalent amount
of intact cells were resuspended into 3.75 ml of LB medium containing
TABLE I
E. coli strains and plasmids
Strain or plasmid Relevant characteristicsa Source or Ref.
Strains
Top10 F hsdRMS recA1 Invitrogen
DH5a hsdR17 recA1 35
MC4100 K-12 laboratory strain 36
O111::B4 Smooth laboratory strainc 37
W3110 K-12 laboratory strain 4
WD2 ts msbA mutant derivative of W3110 4
WD201 ts msbA pmrA mutant derivative of W3110 5
CAG12077 crcA::Tn10 CGSCb
Plasmids
pCRII-TOPO Cloning vector, Kmr, Apr Invitrogen
pCRII-TOPO-crcA pCRII-TOPO containing crcA This study
pET11a Expression vector, Apr Novagen
pET11a-crcA pET11a containing crcA This study
pMMB67EH Expression vector, Apr 38
pMMB67EH-crcA pMMB67EH containing crcA This study
a Kmr, kanamycin-resistant; Apr, ampicillin-resistant.
b E. coli Genetic Stock Center.
c Contains LPS molecules with an O-antigen.
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0.25 M sucrose and labeled for 25 min with 20 Ci of [1-14C]sodium
acetate at 37 °C. Pellets obtained from labeled cells or spheroplasts
were resuspended in 160 l phosphate-buffered saline (pH 7.4). Alter-
natively, pellets were resuspended, sonicated, and fractionated as de-
scribed in isopycnic sucrose gradient centrifugation section.
Phospholipid Analysis—Phospholipids were isolated from resus-
pended spheroplasts or medium fractions obtained after spheroplast
release assays or from 200 l of 1-ml sucrose fractions using a two-
phase lipid extraction method (27). The total amount of radioactive
phospholipids was determined by scintillation counting in 5 ml of Li-
poluma Plus (LUMAC) using a 1209 Rackbeta LSC (LKB Wallac).
Phospholipids were routinely separated by TLC. The plates (silica gel
60, 20 10 cm, Merck) were developed with chloroform/methanol/acetic
acid at a ratio of 65:25:10 and subjected to autoradiography.
RESULTS
Release of Lipoproteins from Spheroplasts—Previously, it
has been demonstrated that de novo synthesized lipoproteins
can be released from spheroplasts upon addition of concen-
trated periplasmic extracts containing the chaperone LolA (12).
Here, we wished to determine whether such extracts contain a
chaperone for the release of LPS as well. Thus, concentrated
periplasmic extracts were prepared as described and first
tested for their activity in the release of Lpp. Indeed, de novo
synthesized Lpp was released from the spheroplasts into the
medium, specifically and efficiently, upon addition of either
purified LolA or a concentrated periplasmic fraction (Fig. 1).
With different batches of periplasmic extracts, the efficiency of
Lpp release was variable (ranging from 30 to 80%). Quantifi-
cation by Western blotting revealed that the amount of LolA in
these periplasmic fractions correlated with their efficiency in
releasing Lpp (data not shown). Thus, de novo synthesized Lpp
was released from spheroplasts in a LolA-dependent manner.
Failure to Release LPS from Spheroplasts—We subsequently
investigated the possibility to release newly synthesized LPS
from spheroplasts by addition of periplasmic extracts. Sphero-
plasts were incubated with [1-14C]sodium acetate to label, un-
specifically, LPS. After labeling, the spheroplasts were sepa-
rated from the medium by centrifugation and both fractions
were analyzed by SDS-PAGE and autoradiography. All newly
synthesized LPS remained associated with the spheroplasts
both in the absence and in the presence of concentrated
periplasmic fractions (Fig. 2). Even much further concentrated
periplasmic fractions did not stimulate LPS release (data not
shown). Similar results were obtained when LPS was specifi-
cally labeled with N-acetyl-D-[1-14C]glucosamine, a precursor
of lipid A (data not shown).
Since acetate enters the general metabolic pathway, also
proteins were labeled with [14C]acetate. Several de novo syn-
thesized proteins were released from spheroplasts even in the
absence of a periplasmic extract (Fig. 2), consistent with the
previously reported release of periplasmic proteins and OMPs
from spheroplasts (28). By immunoprecipitation, one of the
released proteins could be identified as porin OmpC (data not
shown). At least two proteins, indicated with an asterisk in Fig.
2, were released only in the presence of periplasmic extract.
Most likely, they represent lipoproteins.
The results of these experiments suggest that LPS cannot be
released (in a soluble form) from spheroplasts by periplasmic
components. An alternative explanation could be that LPS
after being released from spheroplasts forms aggregates that
co-fractionate with the spheroplasts. To test this possibility,
different amounts of purified 14C-labeled LPS were added to a
spheroplasts suspension, and we investigated whether this
LPS formed aggregates that co-fractionated with spheroplasts.
However, after centrifugation, more than 98% of the labeled
LPS molecules remained in the supernatant fractions. There-
fore, we conclude that de novo synthesized LPS molecules re-
main associated with spheroplasts in the absence and presence
of periplasmic components.
Localization of de Novo Synthesized LPS in Spheroplasts—It
has been described that part of the OM remains attached to the
IM in spheroplasts (29). Therefore, we considered the possibil-
FIG. 1. Release of de novo synthesized Lpp from spheroplasts.
Spheroplasts generated from strain MC4100 were pulse-labeled with
[35S]cysteine/methionine for 3 min in the presence of 3.8 g of purified
LolA, 20 mM Tris-HCl (pH 8.0) (Buffer), or 50 l of concentrated
periplasmic extract (Periplasm). After 4-min chase with unlabeled Cys/
Met, spheroplasts were separated from the medium by centrifugation,
and the proteins in the supernatant fractions were concentrated by
trichloroacetic acid precipitation. Lpp was subsequently immunopre-
cipitated from the medium (M) and spheroplast fractions (S) and ana-
lyzed by SDS-PAGE. The gel was dried and exposed on film.
FIG. 2. Newly synthesized LPS remains associated with the
spheroplasts. Spheroplasts generated from strain MC4100 were la-
beled with [1-14C]sodium acetate for 4 min in the presence of 50 l of
concentrated periplasmic extract (Periplasm) or 20 mM Tris-HCl (pH
8.0) (Buffer). After 4-min chase with unlabeled sodium acetate, sphero-
plasts were separated from the medium by centrifugation. The super-
natant fraction was concentrated by trichloroacetic acid precipitation
and medium (M) and spheroplast (S) fractions were analyzed by SDS-
PAGE. The gel was dried and exposed on film. The positions of molec-
ular mass markers (in kDa) are indicated at the left. Proteins released
upon addition of periplasmic fraction are marked with an asterisk, and
also the positions of the porins and OmpA are indicated (P).
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ity that LPS, synthesized de novo in spheroplasts, might still be
transported to the OM. To investigate this possibility, pulse-
labeled spheroplasts generated from strain MC4100 were dis-
rupted by sonication and fractionated by isopycnic sucrose gra-
dient centrifugation. More then 90% of the IM marker lactate
dehydrogenase was localized in the low density membrane
fractions, whereas the porins were mainly present in the high
density membrane fractions (data not shown). Also most LPS
molecules, which were synthesized prior to the conversion of
the cells to spheroplasts, were found in the high density mem-
brane fractions when analyzed on a silver-stained gel (data not
shown). Interestingly, the radiolabeled LPS molecules were
equally distributed among the low density (inner) membrane
fractions and the high density (outer) membrane fractions (Fig.
3). Apparently, a substantial proportion of the de novo synthe-
sized LPS molecules was translocated to the (remnants of the)
OM in the spheroplasts. The addition of concentrated periplas-
mic extracts during the labeling did not affect the localization
of the newly synthesized LPS (data not shown).
Inactivation of MsbA Prevents the OM Localization of de
Novo Synthesized LPS in Spheroplasts—To exclude any arti-
facts in the procedure described in the previous section, we
determined whether the OM localization of LPS in sphero-
plasts was dependent on the MsbA protein, which is required
for the transport of LPS across the IM. When spheroplasts from
the ts msbA mutant strain WD201 were labeled with [14C]ace-
tate at the permissive temperature, the newly synthesized LPS
fractionated mainly in the high density OM fractions in a
sucrose gradient (Fig. 4), similarly as observed in spheroplasts
from MC4100 (as described above). However, when the sphero-
plasts were labeled after 30-min incubation at the restrictive
temperature (44 °C), the de novo synthesized LPS accumulated
in the low density membrane fractions corresponding to the IM
(Fig. 4). Newly synthesized LPS in spheroplasts generated
from the isogenic wild-type strain W3110 that were similarly
treated and labeled at 44 °C fractionated normally in the OM
fractions of a sucrose gradient (data not shown). This demon-
strates that LPS transport to the OM in spheroplasts is de-
pendent on a functional MsbA protein as described previously
and was confirmed in the present study (data not shown) for
intact cells (4).
De Novo Synthesized LPS Molecules Are Modified by CrcA in
Spheroplasts—To confirm that LPS can indeed be transported
to the OM in spheroplasts, we determined whether the OM
protein CrcA could modify these LPS molecules. CrcA, also
known as PagP, transfers a palmitate residue from the sn-1
position of a phospholipid to the N-linked hydroxymyristate on
the proximal unit of lipid A (30). From its recently solved
structure, CrcA was predicted to have its active site on the edge
of the outer leaflet of the OM (31).
To apply this approach, cells producing CrcA (CAG12077-
pMMB67EH-crcA) or not (CAG12077-pMMB67EH) were con-
verted to spheroplasts and labeled with [14C]acetate. Subse-
quently, their lipid A species were isolated and analyzed by
TLC. Indeed, hepta-acylated lipid A species were produced
abundantly in spheroplasts from cells expressing CrcA (indi-
cated by arrows in Fig. 5), and these species were absent in
those of the crcA disruption mutant CAG12077 carrying the
empty vector (Fig. 5). The CrcA-modified lipid A species that
were observed in the spheroplasts migrated to the same posi-
tion as the lipid A species produced in labeled intact cells (Fig.
5). When these labeled spheroplasts were fractionated on a
sucrose gradient, and the different fractions were analyzed for
their lipid A species, the majority (90%) of the CrcA-modified
lipid A species was present in the high density OM fractions
FIG. 3. Localization of newly synthesized LPS molecules by
sucrose gradient centrifugation. Spheroplasts generated from
strain MC4100 were pulse-labeled for 1 min with 2 Ci of [1-14C]sodium
acetate, followed by a chase with unlabeled acetate for 30 min. The
spheroplasts were disrupted by sonication, and the lysates were applied
to the top of a discontinuous sucrose density gradient. After centrifu-
gation, 1-ml fractions were collected and analyzed by SDS-PAGE. The
gel was dried and exposed on film. Molecular mass markers (in kDa) are
indicated at the left. Fractions 1–3 contained soluble proteins, fractions
5–7 (low density membrane) contained more than 90% of the IMmarker
lactate dehydrogenase, fractions 9–11 (high density membrane) con-
tained the major part of the porins, and fraction 12 was collected from
the bottom of the tube.
FIG. 4. Localization of de novo synthesized LPS in sphero-
plasts of the ts msbA mutant WD201. WD201 cells were converted
into spheroplasts, preincubated for 30 min at the label temperature,
and subsequently labeled for 25 min with 80 Ci of [14C]acetate at 30 °C
(dashed line) or at 44 °C (solid line). After separation of the membranes
on a sucrose gradient, 12 fractions of 1 ml were taken, and lipid A was
isolated from each fraction. The amount of radiolabeled lipid A in each
fraction was determined by liquid scintillation counting and is repre-
sented as the percentage of the total counts. The experiment has been
repeated three times, and the results of a representative experiment
are shown.
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(data not shown), whereas the lipid A species in the IM frac-
tions were not modified by CrcA. In conclusion, the results
show that CrcA indeed modifies newly synthesized LPS mole-
cules produced in spheroplasts. Since these modifications occur
in the OM, these results confirm that LPS is indeed trans-
ported to the OM in spheroplasts.
Transport of de Novo Synthesized Phospholipids Is Defective
in Spheroplasts—In the previous sections, we demonstrated
that LPS is transported to the OM in spheroplasts. We subse-
quently investigated the fate of newly synthesized phospholip-
ids in spheroplasts. When intact cells of themsbAmutant WD2
were labeled at the permissive temperature of 30 °C with
[14C]acetate, and the membranes were separated by isopycnic
sucrose gradient centrifugation, de novo synthesized phospho-
lipid molecules were found in both the low density (IM) and
high density membrane (OM) fractions (Fig. 6). In contrast, in
spheroplasts, the vast majority of de novo synthesized phos-
pholipids localized in the low density membrane fractions (Fig.
6). Similar results were found when the wild-type strains
W3110 and MC4100 were used (data not shown). These results
demonstrate that the transport of newly synthesized phospho-
lipids is defective in spheroplasts.
Possibly, the transport of phospholipids to the OM requires
periplasmic components analogous to LolA that were removed
by spheroplast formation. To evaluate this possibility, we in-
vestigated whether phospholipids were released when sphero-
plasts were labeled in the presence of a periplasmic extract.
However, these extracts did not enhance the release of phos-
pholipids from the spheroplasts (data not shown). In addition,
periplasmic extracts did not change the distribution of newly
synthesized phospholipids between IM and OM of the sphero-
plasts (data not shown).
Taken together, we conclude that phospholipid transport to
the OM is defective in spheroplasts, where at least a significant
proportion of the LPS molecules is still transported to the OM.
Thus, LPS and phospholipids appear to have different require-
ments for their transport through the periplasm.
DISCUSSION
The transport of lipoproteins from the periplasmic side of the
IM to the OM via the Lol system has been characterized in
considerable detail (12, 13, 32). In this study, we have investi-
gated the possibility that LPS is transported to the OM via a
similar mechanism, a possibility also suggested by others (see,
e.g. reference (33). A putative periplasmic chaperone for LPS
might shield the hydrophobic acyl chains of the LPS molecules
from the aqueous periplasm by forming a complex that could
traverse the periplasm and target to the OM. Our results
demonstrate that LPS, in contrast to Lpp, could not be released
in a soluble form from spheroplasts by periplasmic components.
We expect that the periplasmic fractions were concentrated
enough to contain sufficient amounts of this putative compo-
nent. Since the OM contains much more LPS molecules than
lipoproteins, one would expect this putative LPS chaperone to
be at least as abundant as LolA. The latter was present in
sufficient amounts in the isolated periplasmic fractions to re-
lease de novo synthesized Lpp efficiently. OmpA and the porins
were released from the spheroplasts independent of the pres-
ence of a periplasmic extract. If LPS were released from sphero-
plasts, independent of a periplasmic chaperone, it would pos-
sibly form aggregates that could co-fractionate with the
spheroplasts. However, this possibility is unlikely since puri-
fied LPS, added to spheroplasts, remained in the culture su-
pernatant. Thus, it appears that LPS is not released from
spheroplasts, neither in the presence nor in the absence of
periplasmic extracts. This indicates that LPS is transported via
a route different from that of lipoproteins as wells as from that
of integral OMPs.
Previously, electron microscopy studies showed that large
parts of the OM remain attached to the IM of spheroplasts (29),
presumably via some sort of contact sites. When we localized
the newly synthesized LPS produced by the spheroplasts, we
observed that a large proportion of these LPS molecules co-
fractionated with (remnants of) the OM. The distribution of the
FIG. 5. De novo synthesized LPS in spheroplasts is modified by
CrcA. Cells and spheroplasts of crcAmutant strain CAG12077 with the
complementing plasmid pMMB67EH-crcA or with the empty vector
(indicated with  and  CrcA, respectively) were labeled in vivo for 25
min with 20 Ci of [14C]acetate, and lipid A was isolated and analyzed
by TLC followed by autoradiography. Three prominently visible, CrcA-
modified lipid A species are indicated with arrows. The open arrowhead
indicates minor amounts of co-purified phospholipids, which migrate at
this position as seen in a parallel experiment with purified radiolabeled
phospholipids (data not shown).
FIG. 6. Localization of de novo synthesized phospholipids in
intact cells and spheroplasts of strain WD2. WD2 cells (dashed
line) and spheroplasts (solid line) were labeled for 25 min with 80 Ci
of [14C]acetate at 30 °C. After separation of the membrane fractions on
a sucrose gradient, 12 fractions of 1 ml were taken, and phospholipids
were isolated from each fraction. The amount of radiolabeled phospho-
lipids in each fraction was determined by liquid scintillation counting
and is represented as the percentage of the total counts. The experi-
ment has been repeated three times, and the results of a representative
experiment are shown.
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LPS molecules was not affected by the addition of periplasmic
components. To demonstrate that the apparent OM localization
of the LPS was not due to aberrant fractionation behavior of
LPS-containing IM vesicles, we demonstrated that the trans-
port of de novo synthesized LPS molecules to the OM in sphero-
plasts was dependent on a functional MsbA protein. Thus, it
appears that transport of LPS in spheroplasts proceeds via the
pathway that is normally used in intact cells. Furthermore, we
confirmed the correct localization of newly synthesized LPS
molecules to the OM of spheroplasts by demonstrating that
these molecules were modified by CrcA in the OM. Together,
this shows that transport of LPS is possible in spheroplasts,
presumably via the contact sites between the IM and OM.
Interestingly, a role for the zones of adhesion between IM and
OM in the transport of LPS has been suggested previously,
based on the observation that newly synthesized LPS mole-
cules appeared at specific connection sites between IM and OM
in freeze-etched Salmonella typhimurium (34). Although the
nature of such contact sites is unknown, they might be formed
by proteins. Parts of the OM are known to remain attached to
spheroplasts (29), probably via such contact sites. Therefore,
our results are consistent with the transport of LPS to the OM
via the contact sites.
In contrast to LPS, newly synthesized phospholipids did not
fractionate with the high density OM in sucrose gradients,
indicating that their transport is abolished in spheroplasts. It
was proposed previously (4) that the transport of LPS and
phospholipids share a common component at the level of the
IM, MsbA. If phospholipids would subsequently continue on
the same route of transport as LPS, we would have expected
also phospholipid transport to occur in spheroplasts. Since this
was not the case, the mechanism of phospholipid transport
across the periplasm must be different from the mechanism of
LPS transport. We also investigated the possibility that phos-
pholipid transport occurs via a periplasmic chaperone, analo-
gous to the lipoprotein chaperone LolA. However, we were not
able to find evidence for a periplasmic chaperone that releases
de novo synthesized phospholipids from the IM. Thus, the
transport of phospholipids appears to have different require-
ments than that of LPS and lipoproteins. Future research must
focus on elucidating the components involved in the transport
to the OM of both LPS and phospholipids.
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